blue_skies
5 years ago
RMS MEDICAL IS A SPONSOR AND AN EXHIBITOR
IgNS 2019 National Conference. Ig National Society will hold its 8th Annual National Conference at the Red Rock Casino Resort & Spa on October 24-27, 2019. Nurses, pharmacists, physicians, and industry leaders will convene for the only multidisciplinary, comprehensive Ig therapy conference.
IgNS 2019 National Conference - Facebook
https://www.facebook.com โบ events โบ las-vegas-nevada โบ igns-2019-national...
https://ignsconference.com/
If they are going to have another announcement look for super26 needle set coming out party?!
Jlivermore29
5 years ago
Rebranding ??? I guess they've been busy with more than the uplist.
New Ticker Symbol โKRMDโ
CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. (NASDAQ: REPR) (โthe Companyโ) today announced a new dba name, KORU Medical Systems, which the Company will begin using in place of RMS Medical Products on October 24, 2019. Reflecting this change, the Companyโs common stock will commence trading under the new ticker symbol โKRMDโ on the NASDAQ effective October 24, 2019.
blue_skies
5 years ago
The Wednesday intra-day low was $3.20. Today's intr-day low was $3.30. The failure of the stock price to rebound, given an up market today, is problematic and does not bode well short term.
Putting on rose colored glasses, I see that a healthy retrace has occurred.
And there is comfort in the fundamentals of the company, which Craig-Hallum highlighted remain in place. The RMS story is good, the balance sheet is clean. I have faith in the RMS management team to execute the growth plan laid out. The biggest obstacle the company might face is the lack of capacity to meet future demand? This is not a terrible problem to have.
blue_skies
5 years ago
8K John Fletcher replaces Dan Goldberger as Board Chairman
On September 30, 2019, Repro Med Systems, Inc. (โRMS Medicalโ) announced the resignation of Daniel S. Goldberger as the Companyโs Executive Chairman. Mr. Goldberger will remain as a non-executive member of the RMS Medical Board of Directors
the Board of Directors of RMS Medical named R. John Fletcher, a current RMS Medical director, as Chairman.
https://ir.rmsmedicalproducts.com/sec-filings-email/content/0001161697-19-000402/form_8-k.htm
budge
5 years ago
some favorable news about new tech in medication.
Halozyme Therapeutics (NASDAQ:HALO)
Intraday Stock Chart
Today : Friday 13 September 2019
SAN DIEGO, Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated a fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme's ENHANZE® drug delivery technology in combination with intravenous chemotherapy. The study results demonstrated non-inferior levels of Perjeta® in the blood (pharmacokinetics) compared to standard intravenous (IV) infusion of Perjeta® plus Herceptin® and chemotherapy in patients with HER2-positive early breast cancer.
"The results of the phase III FeDeriCa study represent an important development for our ENHANZE® drug delivery technology," said Dr. Helen Torley, President and CEO. "This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our ENHANZE® technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option."
Subcutaneous administration of the fixed-dose combination of Perjeta® and Herceptin® is approximately 8 minutes for the initial loading dose and approximately 5 minutes for each subsequent maintenance dose. Intravenous administration is approximately 150 minutes for the loading dose of Perjeta® and Herceptin® using standard IV formulations and between 60-150 minutes for subsequent maintenance infusions for the combination.
The study also demonstrated that the safety profile of the fixed dose subcutaneous combination of Perjeta® and Herceptin® was consistent with the safety profile of Perjeta® and Herceptin® administered intravenously.
Full data from the FeDeriCa study will be submitted for presentation at an upcoming medical meeting and to health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).1 2
About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. ENHANZE® may also benefit subcutaneous biologics by reducing the need for multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.